Low testosterone and clinical outcomes in Chinese men with type 2 diabetes mellitus – Hong Kong Diabetes Registry. (January 2017)

• Record Type: Journal Article
• Authors: Cheung, Kitty Kit-Ting; Lau, Eric Siu-Him; So, Wing-Yee; Ma, Ronald Ching-Wan; Ozaki, Risa; Kong, Alice Pik-Shan; Chow, Francis Chun-Chung; Chan, Juliana Chung-Ngor; Luk, Andrea On-Yan
• Is Part Of: Diabetes research and clinical practice. Volume 123(2017)
• Page Start: 97
• Page End: 105
• Publication Date: 2017-01
• Subjects: Testosterone -- Type 2 diabetes -- Metabolic syndrome -- Mortality -- Cancer; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2016.11.012
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Aims: To assess the implications of low testosterone on cardiovascular risk factors, metabolic syndrome (MES) and clinical outcomes in Chinese men with Type 2 Diabetes (T2D). Methods: A prospective cohort study carried out in a university hospital involving a consecutive cohort of 1239 Chinese men with T2D and a median disease duration of 9 years followed up for 4.8 years. Clinical characteristics, frequency of MES, serum total testosterone and clinical events were analyzed. Multivariate logistic regression was performed to examine the independent association of low testosterone with MES after adjustment for confounding covariates. Cox proportional hazards regression analysis was used to derive hazard ratio for clinical outcomes. Results: More men with low testosterone had cardiovascular-renal disease and MES than those with normal testosterone. The adjusted odds ratio (OR) of low testosterone for MES was 2.63 (95% Confidence Interval [CI] 1.56–4.61). After a median follow-up of 4.8 years, the hazard ratio (HR) of low testosterone was 2.22 (95% CI 1.23–4.01) for incident non-prostate cancer. In a multivariate Cox-regression model, the HRs were attenuated but remained significant with adjustment for MES and renal parameters. Conclusions: Chinese men with low testosterone had high prevalence of cardiovascular disease and MES with high incidence non-prostate cancer.